Table 1.
Clinical features of the EFS patient with a heterozygous ZP3 deletion.
| Basal hormones | |||||
|---|---|---|---|---|---|
| hFSH | (3.03–8.08 mIU/mL) | 4.68 | |||
| hLH | (1.80–11.78 mIU/mL) | 3.39 | |||
| E2 | (21–251 pg/mL) | 56 | |||
| Prog | (<0.1–0.3 ng/mL) | 0.17 | |||
| Testo | (0.38–1.97 ng/mL) | 0.56 | |||
| PRL | (5.18–26.53 ng/mL) | 6.26 | |||
| Clinical features with COH cycles | |||||
| Cycle | 1 | 2 | 3 | 4 | 5 |
| (other center) | (other center) | (other center) | (other center) | (our center) | |
| Protocol | Ultra-long | Short | Ultra-long | GnRH antagonist | GnRH antagonist |
| Initial dose of Gn (IU) | 225 | 225 | 225 | NA | 300 |
| Duration of Gn days | 4 | 8 | 9 | NA | 8 |
| No. of COC retrieved | 0 | 0 | 0 | 3 | 0 |
| Empty COCs with ooplasm-like fragments | |||||
hFSH, human follicle-stimulating hormone; hLH, human luteinizing hormone; E2, estradiol; Prog, progestin; Testo, testosterone; PRL, prolactin; Gn, Gonadotropins; COC, cumulus–oocyte complex; NA, not available.